Sunday, April 9, 2017

Sunday Globe Flashback: Changing Diapers

Ooooh, baby's bottom stinks:

"Talc verdict winner says money can’t make up for lost health" by Jim Salter Associated Press  October 29, 2016

ST. LOUIS — When her daughter saw a TV ad for a law firm asking ovarian cancer victims who used talcum powder to come forward, Deborah Giannecchini realized a possible link: She had been using Johnson & Johnson’s baby powder for most of her life.

‘‘I used it for 45 years, from age 15,’’ Giannecchini, now 63, said Friday. ‘‘I was still using it.’’

On Thursday, a St. Louis jury awarded more than $70 million to Giannecchini, of Modesto, Calif., wrapping up a monthlong trial. It was the third big verdict awarded by a St. Louis jury against Johnson & Johnson in ovarian cancer lawsuits this year. Combined, the three awards amount to nearly $200 million.

Giannecchini said she was happy with the verdict, but it doesn’t make up for the cancer fight and ongoing health problems caused by chemotherapy.

‘‘There’s not enough money in the world to pay for fighting the cancer,’’ she said at a news conference arranged by her lawyers.

A spokeswoman for Johnson & Johnson said in a statement that while the company sympathizes with women and their families affected by ovarian cancer, it will appeal the latest verdict ‘‘because we are guided by the science, which supports the safety of Johnson’s Baby Powder.’’

About 2,000 women nationwide have filed similar suits over concerns about health damage caused by extended talcum powder use. Lawyers are reviewing many additional cases, many of them generated by television ads by law firms.

In February, a St. Louis jury awarded $72 million to relatives of an Alabama woman who died of ovarian cancer. Another jury awarded $55 million in May to a South Dakota survivor of the disease.

But two cases in New Jersey were thrown out by a judge who said there wasn’t reliable evidence that talc leads to ovarian cancer, an often fatal but relatively rare form of cancer.

Ovarian cancer accounts for about 22,000 of the 1.7 million new cases of cancer expected to be diagnosed in the United States this year. Factors known to increase a women’s risk of ovarian cancer include age, obesity, use of estrogen therapy after menopause, not having any children, certain genetic mutations, and personal or family history of breast or ovarian cancer.

Talc is a mineral that is mined from deposits around the world, including the United States. The softest of minerals, it’s crushed into a white powder. It’s been widely used in cosmetics and other personal care products to absorb moisture since at least 1894, when Johnson & Johnson’s baby powder was launched. But it’s mainly used in a variety of other products, including paint and plastics.

Much research has found no link or a weak one between ovarian cancer and using baby powder for feminine hygiene, and most major health groups have declared talc harmless. Still, the International Agency for Research on Cancer classifies genital use of talc as ‘‘possibly carcinogenic.’’

Attorneys with Onder, Shelton, O’Leary & Peterson, the firm that handled all three St. Louis cases, cited other research that began connecting talcum powder to ovarian cancer in the 1970s. They cite case studies showing that women who regularly use talc on their genital area face up to a 40 percent higher risk of developing ovarian cancer.

The firm has also accused Johnson & Johnson of marketing toward overweight women, blacks, and Hispanics — the very same women most at-risk for ovarian cancer.

Wylie Blair, an attorney for Giannecchini, said there has been no talk with Johnson & Johnson about a class-action settlement.

‘‘Acknowledging that a seminal product that everybody identifies with the company has been causing a horrible disease for all these years is going to be a tough pill to swallow for them,’’ Blair said....



Tesaro’s ovarian cancer drug wins early approval

Time to nurse:

"Study questions value of mammograms, breast cancer screening" by Marilynn Marchione Associated Press  October 13, 2016

A new study questions the value of mammograms for breast cancer screening. It concludes that a woman is more likely to be diagnosed with a small tumor that is not destined to grow than she is to have a true problem spotted early.

The work could further shift the balance of whether a screening’s harms outweigh its benefits. Screening is only worthwhile if it finds cancers that would kill, and if treating them early improves survival versus treating when or if they ever cause symptoms. Treatment has improved so much over the years that detecting cancer early has become less important.

Mammograms do catch some deadly cancers and save lives. But they also find many early cancers that are not destined to grow or spread and become a health threat. There is no good way to tell which ones will, so many women get treatments they don’t really need. It’s a twin problem: overdiagnosis and overtreatment.

Whether to have a mammogram ‘‘is a close call, a value judgment,’’ said study leader Dr. H. Gilbert Welch of Dartmouth Medical School. ‘‘This is a choice and it’s really important that women understand both sides of the story, the benefits and harms.’’

Welch has long argued that mammograms are overrated, and the study parallels work he published from the same data sources four years ago. This time, the authors include Dr. Barnett Kramer, a National Cancer Institute screening expert, although the conclusions are not an official position of the agency....